Rain Oncology's stock dives after tumor treatment fails a PhIII trial
Rain Oncology’s treatment for dedifferentiated liposarcoma failed a Phase III clinical trial, raising questions about what’s next for the Bay Area biotech’s lead candidate.
On Monday, Rain Oncology unveiled data from its MANTRA trial investigating milademetan, an oral small molecule inhibitor, in patients with dedifferentiated liposarcoma, a rare type of cancer that is found in the soft tissue. The trial did not meet its primary endpoint of progression-free survival compared to trabectedin, the standard of care. Johnson & Johnson markets Yondelis, the brand name version of trabectedin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.